PRESS RELEASE
News
-
-
PRESS RELEASE
Disposal of interests in Acacia Estates and Bora Africa to the group’s development subsidiary, Gateway Real Estate Africa
Grit Real Estate Income Group announces disposal of interests in Acacia Estates and Bora Africa to its development subsidiary, Gateway Real Estate Africa, in a related party transaction. The proceeds will be used for the GREA Capital Raise -
PRESS RELEASE
Orogen Royalties Provides Year-End Royalty Update and 2024 Forecast
Orogen Royalties Inc. provides a 2023 year-end update on its royalty portfolio and forecast for 2024, including production data from Ermitaño mine in Mexico and the Expanded Silicon project in Nevada, as well as advancements on various other royalty assets -
-
PRESS RELEASE
Applied UV Inc. Announces Receipt of Provisional Patent for Our Pulse Modulated UVC LED System to be Added to Our Patented Fighter Flex LED Solution Expanding Significant Revenue Opportunity
Applied UV Inc. introduces pulse modulated UVC LED enhancement to Fighter Flex LED solution, expanding revenue opportunity in HVAC industry. Major potential for energy and cost savings -
PRESS RELEASE
Komet Sales and Axerrio Combine to Expand Their Leading B2B Floral E-Commerce Network Across Europe and the Americas
Komet Sales, the leading software provider for the floral industry in the Americas, announces merger with Axerrio, a leading software provider for the floral industry in Europe. The merger aims to benefit customers by increasing access to new features and an expanded network of buyers and sellers -
PRESS RELEASE
Cotec Holdings Corp. Provides Operational Overview and 2024 Key Targets
CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) reports 2023 operational highlights and 2024 targets. Initiated strategic investments, completed name change, and listed on TSXV. Focus on sustainable resource production and transformative technologies -
-
PRESS RELEASE
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found
NanoViricides, Inc. successfully completes Phase 1a/1b Clinical Trial of NV-CoV-2, reporting excellent safety and broad-spectrum antiviral activity of NV-387 against various respiratory viruses including Coronaviruses and RSV -
